Trial Profile
A Single-arm, Multi-center, Phase II Study to Evaluate Efficacy and Safety of Dovitinib (TKI258) in Adult Patients With Advanced Scirrhous Gastric Carcinoma That Have Progressed After One or Two Prior Systemic Treatments.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Feb 2017
Price :
$35
*
At a glance
- Drugs Dovitinib (Primary)
- Indications Adenocarcinoma; Gastric cancer; Neoplasms by site
- Focus Therapeutic Use
- Sponsors Novartis
- 09 Jan 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 16 Apr 2012 New trial record